Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?

Benznidazole vs benznidazole in multilamellar liposomes: how different they interact with blood components?

In spite of its widespread use, benznidazole's (BNZ) toxicity and low efficacy remains as major drawbacks that impair successful treatments against Chagas disease. Previously, attempting to increase the selectivity and reduce its toxicity on infected tissues, multilamellar liposomes (MLV) compo...

Full description

Bibliographic Details
Main Authors:	Maria Jose Morilla, Maria Jimena Prieto, Eder Lilia Romero
Format:	Article
Language:	English
Published:	Fundação Oswaldo Cruz (FIOCRUZ) 2005-04-01
Series:	Memorias do Instituto Oswaldo Cruz
Subjects:	liposomes benznidazole Chagas disease
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S0074-02762005000200017

Similar Items

Benznidazole levels in blood vary with age in rats
by: Romina Fernanda Bulffer, et al.
Published: (2011-05-01)

Pharmacokinetic and pharmacodynamic responses in adult patients with Chagas disease treated with a new formulation of benznidazole
by: Marisa Liliana Fernández, et al.
Published: (2016-03-01)

Tolerance and Adherence of Patients with Chronic Chagas Disease Treated with Benznidazole
by: Cristina Vázquez, et al.
Published: (2023-01-01)

Transcriptomic analysis of benznidazole-resistant and susceptible Trypanosoma cruzi populations
by: Davi Alvarenga Lima, et al.
Published: (2023-05-01)

Ideal benznidazole dose regimen in chronic chagasic patients: a systematic review
by: Virgínia Paula Frade, et al.
Published: (2020-07-01)

Benznidazole-Loaded Polymeric Nanoparticles for Oral Chemotherapeutic Treatment of Chagas Disease
by: Lucas Resende Dutra Sousa, et al.
Published: (2024-06-01)

Parasitemia and antibody response to benznidazole treatment in a cohort of patients with chronic Chagas disease
by: Carlos Henrique Valente Moreira, et al.
Published: (2023-09-01)

Benznidazole biotransformation in rat heart microsomal fraction without observable ultrastructural alterations: comparison to Nifurtimox-induced cardiac effects
by: María Montalto de Mecca, et al.
Published: (2008-09-01)

Trypanosoma cruzi benznidazole susceptibility in vitro does not predict the therapeutic outcome of human Chagas disease
by: Margoth Moreno, et al.
Published: (2010-11-01)

Effects of Free and Nanoencapsulated Benznidazole in Acute <i>Trypanosoma cruzi</i> Infection: Role of Cholinergic Pathway and Redox Status
by: Aniélen D. da Silva, et al.
Published: (2024-10-01)

Long term evaluation of etiological treatment of Chagas disease with benznidazole
by: J. Romeu CANÇADO
Published: (2002-02-01)

Evaluation of parasitemia by qPCR in patients with chronic Chagas disease treated with benznidazole
by: Bianca Sabaini Pavan Tycha, et al.
Published: (2023-01-01)

Benznidazole Treatment: Time- and Dose-Dependence Varies with the <i>Trypanosoma cruzi</i> Strain
by: Kátia da Silva Fonseca, et al.
Published: (2021-06-01)

Solid Nanomedicines of Nifurtimox and Benznidazole for the Oral Treatment of Chagas Disease
by: Miriam Rolon, et al.
Published: (2022-08-01)

Nanostructured lipid carriers containing benznidazole: physicochemical, biopharmaceutical and cellular in vitro studies
by: Giuliana Muraca, et al.
Published: (2023-07-01)

Benznidazole-induced genotoxicity in diploid cells of Aspergillus nidulans
by: Edilson N Kaneshima, et al.
Published: (2005-05-01)

Poly-ε-Caprolactone Implants for Benznidazole Prolonged Release: An Alternative to Chagas Disease Oral Treatment
by: Ana Lia Mazzeti, et al.
Published: (2023-04-01)

Repurposing the Antidiabetic Drugs Glyburide, Gliquidone, and Glipizide in Combination with Benznidazole for <i>Trypanosoma cruzi</i> Infection
by: Citlali Vázquez, et al.
Published: (2024-12-01)

Chronic Chagas cardiomyopathy: a review of the main pathogenic mechanisms and the efficacy of aetiological treatment following the BENznidazole Evaluation for Interrupting Trypanosomiasis (BENEFIT) trial
by: Anis Rassi Jr, et al.

A novel ABCG-like transporter of Trypanosoma cruzi is involved in natural resistance to benznidazole
by: Bianca Zingales, et al.
Published: (2015-05-01)

Efficacy of benznidazol treatment for asymptomatic chagasic patients from state of Rio Grande do Sul evaluated during a three years follow-up
by: CD Fernandes, et al.
Published: (2009-02-01)

A serological, parasitological and clinical evaluation of untreated Chagas disease patients and those treated with benznidazole before and thirteen years after intervention
by: Girley Francisco Machado-de-Assis, et al.
Published: (2013-11-01)

Variation in susceptibility to benznidazole in isolates derived from Trypanosoma cruzi parental strains
by: Veloso VM, et al.
Published: (2001-01-01)

In Vitro Benznidazole and Nifurtimox Susceptibility Profile of Trypanosoma cruzi Strains Belonging to Discrete Typing Units TcI, TcII, and TcV
by: Susana Revollo, et al.
Published: (2019-10-01)

Serological based monitoring of a cohort of patients with chronic Chagas disease treated with benznidazole in a highly endemic area of northern Argentina
by: Leticia L Niborski, et al.
Published: (2016-06-01)

Up-regulation of ATP-binding cassette transporters in the THP-1 human macrophage cell line by the antichagasic benznidazole
by: Virginia G Perdomo, et al.

Nanomedicines against Chagas disease: a critical review
by: Maria Jose Morilla, et al.
Published: (2024-03-01)

Modulation of Trypanosoma cruzi-specific T-cell responses after chemotherapy for chronic Chagas disease
by: María Cecilia Albareda, et al.
Published: (2015-05-01)

Determinación de la sensibilidad in vitro de diferentes cepas de Trypanosoma cruzi al benznidazol y al extracto de hoja de la planta Zanthoxylum chiloperone
by: R Hamuy, et al.
Published: (2013-12-01)

Trypanosoma cruzi: parasite antigens sequestered in heart interstitial dendritic cells are related to persisting myocarditis in benznidazole-treated mice
by: Renata Siqueira Portella, et al.
Published: (2009-11-01)

Overexpression of eukaryotic initiation factor 5A (eIF5A) affects susceptibility to benznidazole in Trypanosoma cruzi populations
by: Douglas de Souza Moreira, et al.
Published: (2018-07-01)

Spectroscopic (FT-IR and FT-Raman) and quantum chemical study on monomer and dimer of benznidazole from DFT and molecular docking approaches
by: Tirth Raj Paneru, et al.
Published: (2025-02-01)

Looking for combination of benznidazole and Trypanosoma cruzi-triosephosphate isomerase inhibitors for Chagas disease treatment
by: Elena Aguilera, et al.

Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease
by: Jaquelline Carla Valamiel de Oliveira-Silva, et al.
Published: (2015-02-01)

Trypanosoma cruzi: chemotherapy with benznidazole in mice inoculated with strains from Paraná State and from different endemic areas of Brazil
by: Max Jean de Ornelas TOLEDO, et al.
Published: (1997-09-01)

Etiological drug treatment of human infection by Trypanosoma cruzi Tratamento etiológico por droga da infecção humana pelo Trypanosoma cruzi
by: Guido Carlos Levi, et al.
Published: (1996-02-01)

The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease
by: J Antonio Marin-Neto, et al.
Published: (2009-07-01)

Benznidazole as Prophylaxis for Chagas Disease Infection Reactivation in Heart Transplant Patients: A Case Series in Brazil
by: Joao Manoel Rossi Neto, et al.
Published: (2020-08-01)

Impact of antiparasitic therapy on cardiovascular outcomes in chronic Chagas disease. A systematic review and meta-analysisResearch in context
by: Anis Rassi, Jr, et al.
Published: (2025-01-01)

Persistent infections in chronic Chagas' disease patients treated with anti-Trypanosoma cruzi nitroderivatives
by: M. Socorro BRAGA, et al.
Published: (2000-06-01)